Chiesi Farmaceutici S.p.a.

Fausto Pivetti

Alessandro Falchi

Emilio Lutero

Emanuele Ferrari

Rocco Bussolati

Edoardo Mariani

Orsola Vecchi

Erhard Bappert

Caterina Ventrici

Maurizio Delcanale

Monica Bocchi

David Andrew Lewis

Brian John Meakin

Francesca Schiaretti

Alessandro Cavecchi

Cristiana Merusi

Gabriele Amari

Paolo Chiesi

Paolo Ventura

Vittorino Servadio

David Ganderton

Maria Gioia Fornaretto

Annamaria Soliani Raschini

Andrea Capocchi

Roberto Pighi

Bluetta Salsi

Claudio Pietra

Enrico Vigano

Ernesto Landonio

Marco Re

Stefano Luca Giaffreda

Marco Curzi

Benoit Folleas

Hubert Botte

Thomas Delacroix

The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.

Process for the preparation of a PDE4 inhibitor

A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta-adrenoceptor agonist, and a corticosteroid is provided.

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

A process for preparing a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta-adrenoceptor agonist, and, optionally, an inhaled corticosteroid, is provided.

A new crystal form of threo glycopyrronium chloride is useful in pharmaceutical applications.

Crystal form of glycopyrronium chloride

Compounds according to formula (IA): may be efficiently prepared by the disclosed process.

Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid

Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be phosphoric acid or sulphuric acid.

Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent

Novel polymorphic forms and salts of 1-(3',4&#x2032;-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease.

Polymorphs and salts

Reconstituted pulmonary surfactants comprising a lipid carrier, a combination of polypeptide analog of the native surfactant protein SP-C with a particular polypeptide analog of the native surfactant protein SP-B may be used for the treatment or prophylaxis of RDS and other respiratory disorders.

Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)

8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride of formula (I) may be conveniently prepared in a diastereomeric pure form from optically pure precursors that are readily available by simple resolution and asymmetric reduction.

Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride

Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is disclosed.

Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation

Growing community of inventors

Parma, Italy

Fausto Pivetti